The United States Patent and Trademark Office (USPTO) has issued patent US12582546B2 to Femasys Inc. This patent covers methods and devices for the controlled delivery of various material compositions, including occlusive, therapeutic, and diagnostic agents. The patent was filed on August 21, 2023, and officially granted on March 24, 2026, with 16 claims.

As this is a patent grant, it represents an intellectual property right rather than a regulatory mandate. Companies in the medical device and pharmaceutical sectors, particularly those involved in drug delivery systems, should be aware of this granted patent as it may impact their own product development and intellectual property strategies. No immediate compliance actions are required for entities outside of Femasys Inc.